Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Research
    • Structural Heart Disease
    • TAVR
    • Therapies
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe

Search form

Home
News You Need to Know Today
Breaking News: Shockwave’s IVL technology gains FDA approval for treating advanced coronary artery disease
Tuesday, February 16, 2021
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Breaking News

Shockwave’s IVL technology gains FDA approval for treating advanced coronary artery disease

Shockwave Medical announced Tuesday, Feb. 16, that intravascular lithotripsy (IVL) has gained FDA approval for the treatment of severely calcified coronary artery disease.

READ MORE >
The Shockwave Medical M5+ new peripheral intravascular lithotripsy (IVL) catheter cuts procedures times in half and was showed for the first time at the American College of Cardiology (ACC) 2022 meeting. It is designed to break up calcium in heavily calcified arteries to avoid the need for vessel trauma caused by high pressure angioplasty.
Share on Twitter Share on Facebook Share on Linkedin

Shockwave’s IVL technology gains FDA approval for treating advanced coronary artery disease

Share on Twitter Share on Facebook Share on Linkedin
The Shockwave Medical M5+ new peripheral intravascular lithotripsy (IVL) catheter cuts procedures times in half and was showed for the first time at the American College of Cardiology (ACC) 2022 meeting. It is designed to break up calcium in heavily calcified arteries to avoid the need for vessel trauma caused by high pressure angioplasty.
Shockwave Medical announced Tuesday, Feb. 16, that intravascular lithotripsy (IVL) has gained FDA approval for the treatment of severely calcified coronary artery disease.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Researchers: Online ICD message board littered with inaccuracies
Weekend Edition | April 7, 2018
Female physicians earned $105K less than men in 2017; cardiologists No. 6 in pay

Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page …241
    • Page 242
    • Page 243
    • Page 244
    • Page 245
    • Page 246
    • Page 247
    • Page 248
    • Current page 249
  • Home
  • News
  • Sitemap
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • AI in Healthcare
  • Cardiovascular Business
  • HealthExec
  • Health Imaging
  • Radiology Business
 
© 2024 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme